Immune Therapy Management

ITM Isotope Technologies Munich SE (ITM) is a leading privately held radiopharmaceutical company focused on the development and production of targeted diagnostic and therapeutic agents for oncology. The company's core technology is Targeted Radionuclide Therapy (TRT), which utilizes specific targeting molecules like peptides to deliver medical radioisotopes directly to tumor sites. ITM's lead therapeutic candidate, ITM-11 (n.c.a. 177Lu-edotreotide), is currently in Phase 3 clinical trials for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Beyond its internal drug development, ITM is a critical global supplier of high-purity medical radioisotopes, most notably no-carrier-added Lutetium-177 (EndolucinBeta). The company operates a sophisticated manufacturing and distribution network, providing essential isotopes to major pharmaceutical partners and clinics worldwide. With significant backing from investors like Temasek and BlackRock, ITM is expanding its pipeline to include targets such as Fibroblast Activation Protein (FAP) and Folate Receptor alpha.